

Applicant believes that he responded fully to all of the concerns expressed by the Examiner and respectfully requests that the claims be amended as indicated, and that early favorable action be taken on all claims pending in the application. If the Examiner has any further concerns, Applicant requests a call to Applicant's attorney Patrick Dwyer at (206) 343-7074.

Respectfully submitted,



PATRICK MICHAEL DWYER
Reg. No. 32,411

PATRICK M. DWYER
PROTEOTECH, INC.
1818 WESTLAKE AVENUE N, SUITE 114
SEATTLE, WA 98109

P18-ELEC-PA.RSP



Amended Claims
(Version with Markings to Show Changes Made)

31. A pharmaceutical agent comprising a therapeutically effective amount of a material made according to the process of claims 1, 8, 10-13, 18 or 22, the therapeutic amount of the material selected for efficacy in treating an amyloid disease or a disease related to alpha-synuclein in a patient.
33. The pharmaceutical agent of claim 31 ~~or 32~~ wherein the therapeutically effective amount of a material comprises a dosage in the range of from about 10 to 1,000 mg/kg of body weight of the patient.
35. The pharmacological agent of claim 33 wherein said amyloid disease for treatment is selected from the group of amyloid diseases associated with Alzheimer's disease, Down's syndrome, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, the amyloidosis associated with type II diabetes, the amyloidosis associated with chronic inflammation, various forms of malignancy and Familial Mediterranean Fever, the amyloidosis associated with multiple myeloma and other B-cell dyscrasias, the amyloidosis associated with the prion diseases including Creutzfeldt-Jakob disease, Gerstmann-Straussler syndrome, kuru and animal scrapie, the amyloidosis associated with long-term hemodialysis and carpal tunnel syndrome, and the amyloidosis associated with endocrine tumors such as medullary carcinoma of the thyroid, and the alpha-synuclein associated diseases including is selected from Parkinson's disease and Lewy body disease.

RECEIVED

FEB 10 2003

TECH CENTER 1600/2900